Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow


TORONTO, Sept. 14, 2020 (GLOBE NEWSWIRE) -- Telo Genomics Corp. (TSX-V: TELO) (the “Company” or “TELO”) is pleased to announce that it has launched a commercial evaluation in collaboration with Applied Spectral Imaging (ASI) California to assess the applicability of integrating GenASIs™, the ASI automated imaging and analysis solutions into TELO’s workflow.

Read more here:
Telo Genomics Launches a Commercial Evaluation of Applied Spectral Imaging Automation (AI) with TELO Workflow

Related Posts